Clinical observation of Longxue Shengji ointment combined with bioactive glass in the treatment of chronic refractory wounds
Yingjian Zhang,Ming Yan,Fei Zhang,Chenyu Ma
The Third People’s Hospital Health Care Group of Cixi, 315300
Abstract:Objective:To investigate the therapeutic effect of Longxue Shengji Ointment combined with bioactive glass on chronic refractory wounds. Methods:Forty patients with early-stage chronic refractory wounds admitted to the hospital between June 2023 and December 2024 were selected and randomly divided into a control group and a study group,with 20 patients in each group. The control group was treated with conventional bioactive glass dressing alone,while the study group received Longxue Shengji Ointment combined with bioactive glass dressing. Bacterial culture results,wound healing rate,wound healing time,and healing grade were compared between the two groups. Results:The wound healing time in the study group was significantly shorter than that in the control group,with a statistically significant difference(P < 0.05). Compared with the control group,the wound healing rate and the excellent healing rate were higher in the study group,and the differences were statistically significant(P < 0.05). After treatment,there was no significant difference in the negative rate of bacterial cultures between the two groups(P > 0.05). After treatment,the decrease in inflammatory indicators was more pronounced in the study group than in the control group,with a statistically significant difference(P < 0.05). Conclusion:The combination of Longxue Shengji Ointment and bioactive glass dressing in the treatment of patients with refractory wounds can exert a synergistic effect,shorten the treatment duration,and improve the quality of wound healing.
参考文献 [1] Liao X,Liang J X,Li S H,et al. Allogeneic platelet-rich plasma therapy as an effective and safe adjuvant method for chronic wounds[J]. J Surg Res,2020,246:284-291. [2] Prabhu R,Vijayakumar C,Bosco Chandra A A,et al. Efficacy of homologous,platelet-rich plasma dressing in chronic non-healing ulcers:An observational study[J]. Cureus,2018,10(2):e2145. [3] 朱静,彭旦明. 慢性难愈性创面的治疗研究进展[J]. 实用中西医结合临床,2021,21(19):156-159. [4] Hartwig D,Harloff S,Liu L,et al. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells:A potential agent for the treatment of ocular surface defects?[J]. Transfusion,2004,44(12):1724-1731. [5] 张晓平,罗统富,安忠诚,等. 龙血生肌温敏凝胶应用于失神经支配创面20 例疗效分析[J]. 浙江中医杂志,2020,55(10):735-736. [6] 周来生,廖镇江,张勤,等. 无机活性元素对皮肤创面愈合的生物诱导作用[J]. 中华烧伤杂志,2005,21(5):363-366. [7] 郑筱萸. 中药新药临床研究指导原则:试行[M].中药新药临床研究指导原则:试行,2002. [8] Bjarnsholt T,Kirketerp-M?ller K,Jensen P,et al. Why chronic wounds will not heal:A novel hypothesis[J]. Wound Repair Regen,2008,16(1):2-10. [9] Koivisto L,Heino J,H?kkinen L,et al. Integrins in wound healing[J]. Adv Wound Care(New Rochelle),2014,3(12):762-783. [10] 张士云,唐汉钧,崔全起,等. 复黄生肌愈创油膏减少皮肤创面瘢痕形成的作用机理研究[J]. 上海中医药大学学报,2001,15(2):52-55. [11] 庄兢,林根辉,郑清健. 皮肤创面无机诱导活性敷料对难愈合性创面 i 型胶原蛋白和ⅲ型胶原蛋白表达的影响[J]. 创伤与急诊电子杂志,2018,6(1):17-23. [12] 沈增运,朱业靖,郝帅,等. 复方黄柏液负压滴灌对糖尿病足创面细菌感染生物膜形成的影响[J]. 中华医院感染学杂志,2022,32(19):2992-2996. [13] Yang X,Cao Z,Wu P,et al. Effect and mechanism of the bruton tyrosine kinase(btk)inhibitor ibrutinib on rat model of diabetic foot ulcers[J]. Med Sci Monit,2019,25:7951-7957. [14] Chen X G,Wang Z,Liu W S,et al. The effect of carboxymethyl-chitosan on proliferation and collagen secretion of normal and keloid skin fibroblasts[J]. Biomaterials,2002,23(23):4609-4614. [15] Xia D L,Chen Y P,Wang Y F,et al. Fabrication of waterproof,breathable composite liquid dressing and its application in diabetic skin ulcer repair[J]. Adv Skin Wound Care,2016,29(11):499-508. [16] 李承果,吴庆能,凌钦杰,等. 生肌膏结合封闭负压引流术治疗难愈创口的临床效果观察[J]. 中国当代医药,2014,21(12):91-92+96. [17] 陈军,王裔惟,徐泽宇,等. 基于共生菌群调控诠释外用中药治疗慢性创面机制的认知与思考[J]. 中草药,2022,53(23):7606-7612.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.